Tranzone secures GSK deal

Published: 8-Dec-2011
Finance Logistics

Will store various products in Jebel Ali for distribution to the Gulf and Near East Region

Tranzone Logistics, a subsidiary of Saudia Arabia-based Banaja Holdings, is to store various products for GlaxoSmithKline in its new warehouse in Jebel Ali for distribution to the Gulf and Near East Region.

The deal was signed during the opening ceremony for Tranzone’s new facility.

GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.

Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.

Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.

See more

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Read more
Aims to expand and diversify DEEF facility in Saudi Arabia

Trending Articles

  1. Destination Russia for new NYK Logistics warehouse <p>Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.</p>
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Procurement as a strategic business enabler How Alkermes unlocked $30m in project cost savings with JAGGAER
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Lario Therapeutics secures $2.4m from MJFF and Wellcome to expand CNS calcium channel programmes The company has been awarded $2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's Research and Wellcome to advance its neuronal calcium channel platform into Parkinson's disease and post-traumatic stress disorder
  4. Horizon Europe 2025 grant backs Phase II trial of HER-096 for Parkinson’s disease Herantis Pharma has secured selection for €8m in non-dilutive funding under Horizon Europe to advance a Phase II proof-of-concept study of its subcutaneously delivered Parkinson’s therapy candidate HER-096
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industry partnerships strengthen biopharma innovation and manufacturing pathways The life sciences sector continues to embrace strategic collaborations that bridge discovery and manufacturing gaps, with two major announcements highlighting industry momentum in early 2026

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Aims to expand and diversify DEEF facility in Saudi Arabia
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Finance

Heligan Group report: UK healthcare M&A remains resilient

A new report from the investment group has highlighted the healthcare field as being a "defensive, structurally supported sector"
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Procurement as a strategic business enabler

How Alkermes unlocked $30m in project cost savings with JAGGAER
Finance

Axol Bioscience expands ophthalmology portfolio with acquisition of Newcells Biotech business

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, strengthening its iPSC-derived retinal organoid and RPE model offerings
Finance

Gilead Sciences to acquire Arcellx in $7.8 billion deal to advance Anito-cel

Gilead Sciences has agreed to acquire Arcellx for $7.8bn, gaining full control of investigational CAR T therapy anito-cel following FDA acceptance of its BLA for relapsed/refractory multiple myeloma
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Lario Therapeutics secures $2.4m from MJFF and Wellcome to expand CNS calcium channel programmes

The company has been awarded $2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's Research and Wellcome to advance its neuronal calcium channel platform into Parkinson's disease and post-traumatic stress disorder
Subscribe now